ClinicalTrials.gg
Not yet recruitingNCT06817096Updated Feb 10, 2025

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

A Phase 3 interventional study of Nitazoxanide 600Mg Oral Tablet / placebo oral tablet in Covid 19 and Influenza, sponsored by Azidus Brasil. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Azidus Brasil · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in COVID-19 by Azidus Brasil — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Azidus Brasil.

Planned enrollment
3rd of 10
340 · median 145
Started
2025
the only one that year
Phase 3
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in COVID-19 by Azidus Brasil, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 3, and was the 10th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 10 studies in COVID-19 by Azidus Brasil is open now.

Where they have run

Who these studies take

Of the 355 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 90 take children under 18; 134 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in COVID-19 by Azidus Brasil, or all of them as a file.
02

Study summary

  1. Participants will:
  • Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses.
  • Visit the clinic on the 7th day of treatment for a check-up and safety tests.
  • Keep a diary of their symptoms and other medications used
03

Conditions studied

  • Covid 19
  • Influenza

Keywords

  • nitazoxanide
  • outpatient treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • Male or female;
  • Age ≥ 18 years;
  • COVID-19 or influenza diagnosed by rapid test, with symptom onset less than 48 hours ago;
  • Clinical condition compatible with outpatient treatment.

Exclusion criteria

Exclusion Criteria:

  • Known to nitazoxanide;
  • History of cardiomyopathies, hepatopathies, or nephropathies;
  • Antineoplastic treatment with chemotherapy or radiotherapy;
  • Severe diseases with ;
  • Transplant recipients;
  • Any uncompensated systemic disease at the investigator's discretion;
  • Participation in clinical studies in the last 12 months;
  • Pregnant or breastfeeding individuals;
  • Suspected bacterial coinfection or prescription of antibiotic therapy at enrollment;
  • Diagnosis of neurological disease (traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, other dementias);
  • Diagnosis of developmental disorder (ADHD, ASD, learning disabilities, intellectual disability, Rett syndrome);
  • Significant hearing or vision impairment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
340 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    take placebo orally, twice daily for 7 days.

    Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

  • Experimental
    nitazoxanide

    take nitazoxanide 600 mg orally, twice daily for 7 days

    Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

Interventions

  • DrugNitazoxanide 600Mg Oral Tablet / placebo oral tablet

    1 tablet every 12 hours

06

What researchers measure

Primary outcomes

  1. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of COVID-19

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the time to symptom resolution (fever, cough, runny nose, nasal congestion, sore throat, fatigue, headache, muscle pain, sweating, or chills) from inclusion until fever is absent and the other signs and symptoms reach a score\* of 1 or 0. \*Scores will be classified from 0 to 3, as follows: absent (0), mild (1), moderate (2), or severe (3), according to the Influenza-like Illness Signs and Symptoms Scale (ILISSS).

    Time frame: From enrollment to the end of treatment will last up to 60 days

  2. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of Influenza

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the time to symptom resolution (fever, cough, runny nose, nasal congestion, sore throat, fatigue, headache, muscle pain, sweating, or chills) from inclusion until fever is absent and the other signs and symptoms reach a score\* of 1 or 0. \*Scores will be classified from 0 to 3, as follows: absent (0), mild (1), moderate (2), or severe (3), according to the Influenza-like Illness Signs and Symptoms Scale (ILISSS).

    Time frame: From enrollment to the end of treatment will last up to 60 days

Secondary outcomes

  1. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of COVID-19

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the time to symptom resolution (fever, cough, runny nose, nasal congestion, sore throat, fatigue, headache, muscle pain, sweating, or chills) from inclusion until fever is absent and the other signs and symptoms reach a score\* of 1 or 0, for participants who developed symptoms less than 24 hours before inclusion.

    Time frame: From enrollment to the end of treatment will last up to 60 days

  2. Evaluation of the Effectiveness of Nitazoxanide in the Outpatient Treatment of Influenza

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the time to symptom resolution (fever, cough, runny nose, nasal congestion, sore throat, fatigue, headache, muscle pain, sweating, or chills) from inclusion until fever is absent and the other signs and symptoms reach a score\* of 1 or 0, for participants who developed symptoms less than 24 hours before inclusion.

    Time frame: From enrollment to the end of treatment will last up to 60 days

  3. Evaluation of the Protective Effect of Nitazoxanide on the Development of Cognitive Changes Resulting from COVID-19

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding cognitive impairments observed between V6 and V8 in the following tests: 1. MoCA 2. TMT-A 3. TMT-B

    Time frame: From enrollment to the end of treatment will last up to 60 days

  4. Evaluation of the Protective Effect of Nitazoxanide on the Development of Pulmonary Dysfunction Resulting from COVID-19

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding changes in spirometric parameters observed between V6 and V8: 1. FVC 2. FEV1 3. FVC/FEV1

    Time frame: From enrollment to the end of treatment will last up to 60 days

  5. Evaluation of the Effectiveness of Nitazoxanide in Preventing Bacterial Complications

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the incidence of antibacterial medication prescriptions.

    Time frame: From enrollment to the end of treatment will last up to 60 days

  6. Evaluation of the Effectiveness of Nitazoxanide in Preventing Hospitalization

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the incidence of hospitalization.

    Time frame: From enrollment to the end of treatment will last up to 60 days

  7. Evaluation of the Safety of Nitazoxanide in Participants with COVID-19 or Influenza Under Outpatient Treatment

    The evaluation will be conducted by comparing the nitazoxanide and placebo groups regarding the incidence and classification of treatment-emergent adverse events in terms of type, frequency, and severity.v

    Time frame: From enrollment to the end of treatment will last up to 60 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 22 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 10, 2025
StartEst.
Feb 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06817096
Lead sponsor
Azidus Brasil
Collaborators
Farmoquimica S.A.
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Feb 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion